Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment — VRAP-DAAST  

Virtual Reality Clinical Trial

Official title: Virtual Reality Assisted Patient Empowerment: Diagnose ATTR-Amyloidosis And Start Treatment

Status Not yet recruiting

Clinical Trial Summary

ATTR amyloidosis is a serious condition with significant morbidity and mortality. In Germany, there are numerous unreported cases of untreated patients, and diagnosing and initiating treatment often requires multiple specialized tests. To address this, a study is being conducted to determine if virtual reality (VR)-based patient education can improve diagnosis rates, treatment initiation, and medication adherence compared to standard education methods.

Clinical Trial Description

Tafamidis is effective in reducing mortality and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), and adherence to the drug is generally high. However, the main challenge lies in timely diagnosis and initiation of therapy. Virtual reality (VR) offers an immersive educational tool that surpasses conventional methods like brochures and videos, with patients preferring VR glasses. By preparing patients through VR, they can engage in informed conversations with physicians, understand the diagnostic process better, and be motivated to initiate therapy promptly. VR empowers patients and saves valuable time for physicians, and it has been well-received even among older cardiovascular patients ;

Related Conditions & MeSH terms

• Amyloidosis
• Amyloidosis Cardiac
• Virtual Reality

• NCT number: NCT05938218
• Study type: Interventional
• Source: Heinrich-Heine University, Duesseldorf
• Contact: Raphael Bruno, MD
• Phone: +492118118000
• Email: raphael.bruno@med.uni-duesseldorf.de
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 1, 2023
• Completion date: December 1, 2025